Analyst firms · Robert W. Baird · ARCT
Robert W. Baird ARCT price target and rating history
Arcturus Therapeutics Holdings Inc. (ARCT) · Health Care
Robert W. Baird rates Arcturus Therapeutics Holdings Inc. (ARCT) Underperform with a $18 price target, as of its latest action on Nov 10, 2022. It has published 4 rating actions on ARCT since August 2021, including 1 upgrade and 3 downgrades. Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.
- Current rating
- Underperform
- Price target
- $18
- Median target, all firms
- $20
- Actions on ARCT
- 4
Robert W. Baird price target on ARCT
Every Robert W. Baird rating on ARCT
- Nov 10, 2022
- May 11, 2022
- Aug 10, 2021
- Aug 10, 2021
How other firms rate ARCT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $20 | Sep 24, 2026 |
| B. Riley Securities | Buy | $22 | Mar 18, 2026 |
| Roth Capital | Buy | $20 | Jan 23, 2026 |
Questions about Robert W. Baird and ARCT
- What is Robert W. Baird's price target for ARCT?
- Robert W. Baird's latest stated price target for Arcturus Therapeutics Holdings Inc. (ARCT) is $18, from its action on Nov 10, 2022.
- What is Robert W. Baird's rating on ARCT?
- Robert W. Baird rates ARCT Underperform, a bearish rating, as of Nov 10, 2022.
- When did Robert W. Baird last change its view on ARCT?
- On Nov 10, 2022, Robert W. Baird downgrades to Underperform from Neutral, price target $18.
- How does Robert W. Baird's ARCT target compare with other analysts?
- Across 3 firms with a ARCT price target in the last 12 months, the median target is $20.
More ARCT rating histories
All Robert W. Baird ratingsARCT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.